Novartis AG
Company Snapshot
Founded: 1996
Entity Type: Public
Employees: 75,267
Region: U.S. and Europe
Revenue: $54,532.0 Millions
Revenue Year: 2025
Segment: Oncology
Headquarter: Basel, Switzerland
Key Geographics: U.S., Europe, Asia, Africa, Australasia, Canada, Latin America
Corporate Address: Lichtstrasse 35 CH-4056 Basel, Switzerland Tel: +41-61-324-1111 Web: www.novartis.com
Company Overview
Novartis AG is a Swiss pharmaceutical company established in 1996 by the merger of Ciba-Geigy and Sandoz. Its products include innovative pharmaceuticals, generics, oncology drugs, and biosimilars. Its products are available in 130 countries. After the Sandoz business was spun off, Novartis began operations on October 3, 2023, as a single global operating segment innovative medicines company. Currently, it is developing, producing, distributing, commercializing, and selling innovative medicines.
Financial Highlights (FY 2025)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Novartis AG In News
Company's Business Segments
- Cardiovascular, Renal and Metabolic : Entresto, Leqvio, and Other
- Immunology : Cosentyx, Xolai, Ilaris, and Other
- Neuroscience : Kesimpta, Zolgensma, Mayzent, Aimovig, and Other
- Oncology : Promacta/Revolade, Kisqali, Tafinlar + Mekinist, Tasigna, Jakavi, Pluvicto, Lutathera, Kymriah, Piqray/Vijoice, Scemblix, Votrient, Adakveo, Tabrecta, and other
- Established Brands : Lucentis, Sandostatin, Gilenya, Exforge Group, Galvus Group, Diovan Group, Gleevec/Glivec, Afinitor/Votubia, Contract manufacturing, and Other
Applications/End User Industries
- Cardiovascular
- Immunology
- Neuroscience
- Oncology
- Metabolic
- Renal